Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients ≥18 Years of Age

Next Previous
X
Search
Trial Profile

A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients ≥18 Years of Age

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ecleralimab (Primary) ; Beta 2 adrenergic receptor agonists; Corticosteroid; Leukotriene receptor antagonists; Muscarinic receptor antagonists; Salmeterol/fluticasone propionate; Theophylline
  • Indications Asthma
  • Focus Adverse reactions
  • Acronyms CCSJ117A12201E1
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

    • Most Recent Events

    • 21 Sep 2022 Status changed from recruiting to discontinued.
    • 20 Sep 2022 The trial has been discontinued in Slovakia, according to European Clinical Trials Database record.(Global end date 08/09/2022)
    • 26 Aug 2022 The trial has been completed in Czechia, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top